ROS-induced autophagy reduces B16F10 melanoma cell proliferative activity
Cancer is a pathology characterized by increased cell progression and/or reduced programmed cell death. Melanoma shows a rapid increase in cell progression and its resistance to chemotherapy is associated with uncontrolled apoptosis and to mechanisms that increase the flow of the drug out of the cell. The objective of this study was to evaluate the effects of photodynamic therapy (PDT) on the cell proliferation and cellular alterations in B16F10 murine melanoma. For that, four experimental groups were evaluated: the control group; laser group (ʎ = 660 ηm, 40 mW, 2.4 J/cm2); photosensitizer group (solution containing methylene blue and toluidine blue 1:1–12.5 μg/mL); PDT group. The incubation time was 30 min. Fluorescence microscopy assays were performed without fixation with the DAPI, monodansylcadaverine (MDC), and dihydroethidium (DHE) probes. Cell proliferation was also determined at 24-h time. The tests were performed in triplicate and the statistical test used was ANOVA with Tukey post-test. The results demonstrate that the plasma membrane of the cells of all the experimental groups remained intact, ROS production and autophagy significantly increased (p < 0.0005 and p < 0.0071, respectively) only in the PDT group. The cell proliferation essay showed a reduction of 74.2% on the PDT group in relation to the control group. The present study demonstrated that oxidative stress promoted by photodynamic therapy may induce autophagy and consequently reduce cell proliferation in B16F10 melanoma.
KeywordsCancer Autophagy Photodynamic therapy
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The use of commercial murine cells (Murine melanoma cells B16F10 (ATCC: CRL-6475) does not need the approval of the Ethics Committee according to Brazilian regulations.
- 7.Bursch W, Ellinger A, Gerner C, Schulte-Hermann R (2004) Caspase independent and autophagic cell death. In: Lockshin RA, Zakeri Z (eds) When cells die II. Wiley-Liss, New York, p 275–310Google Scholar
- 8.Pires-Santos GM, Oliveira SCPS, Monteiro JSC, Sampaio FJP, Brugnera A, Zanin FAA, Almeida P, Pinheiro ALB (2015) Prospective study of luminous radiation associated technology photosensitive compounds for treatment of diseases. Proc SPIE 9309:1–7Google Scholar
- 13.Bakr EM (2005) A new soflware for measuring leaf area, and area damaged by Tetranychus uritcae Koch. JEN 129(3):173–175Google Scholar
- 19.Latocha M, Ba AZ, Polaniak R, Kuamierz D, Nowosad A, Jurzak M, Romuk E, Kokocińska M, Sliupkas-Dyrda E (2015) Molecular Effects of Amine Derivatives Of Phenothiazine On Cancer Cells C-32 And Snb-19 In Vitro. Acta Pol Pharma Drug Res 72(5):909–915Google Scholar
- 26.Pandey RK, Joshi P (2014) Synthesis and biological significance of porphyrin-based photosensitisers in photodynamic therapy. In: Vo-Dinh T (ed) Biomedical photonics handbook, 2nd edn. CRC Press, Boca Raton, p 31–65Google Scholar
- 27.Issa MCA, Fassini A, Boechat M, Ferolla ACJ (2016) Photodynamic therapy in photoaging: literature review. Surg Cosmet Dermatol 8(4 Supl. 1):S10–S16Google Scholar
- 28.Wainwright M (2009) Photossensitisers in biomedicine. Wiley-BlackwellGoogle Scholar
- 29.Zelickson BD (2005) Mechanisms of action of topical aminolevulinic acid. In: Goldman MP (ed) Photodynamic therapy, 1st edn. Elsevier Saunders, Philadelphia, p 1–12Google Scholar